Factor XIII Activity
Ordering Recommendation

First-line test to diagnose FXIII deficiency. Appropriate for evaluation of patients with a bleeding disorder who present with normal PT, PTT, and platelet count test results. Use for monitoring FXIII therapy and for confirming abnormalities detected on FXIII qualitative assay.

F13 A
Chromogenic Assay
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lt. blue (sodium citrate). Refer to Specimen Handling at for hemostasis/thrombosis specimen handling guidelines. 
Specimen Preparation
Transfer 2 mL platelet-poor plasma to an ARUP Standard Transport Tube. (Min: 1 mL) 
Storage/Transport Temperature
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. 
Unacceptable Conditions
Serum. EDTA plasma, clotted or hemolyzed specimens. 
Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: at -20°C or below: 1 month; Frozen at -70°C or below: 3 months 
Reference Interval
Factor XIII Activity 69-143%
Interpretive Data
Refer to Statement B under Testing Information at

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
Component Test Code*Component Chart NameLOINC
2006183Factor XIII Activity27815-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Factor 13
  • fibrin stabilizing factor